S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
The study is a two-arm randomised phase III trial. Patients will be randomised to receive
capecitabine (arm A) or S-1 (arm B). Bevacizumab may be added according to the choice of the
investigator. Patients will be followed 3-weekly at the outpatient clinic, toxicity will be
assessed according to study protocol guidelines. Patients will be evaluated every 3 cycles
for response. Upon disease progression patients will be treated according to the local
investigators